You are here : Home >About us  >Advisory Boards

Advisory Boards 

Scientific Advisory Board


  • Professor Luc Montagnier, PhD, Former Research Scientist at L'Institut Pasteur (The Pasteur Institute), Paris, France, a Nobel Laureate and discoverer of the HIV virus
  • Ellen Jo Baron, PhD, Director of the Stanford Clinical Microbiology/Virology Laboratory and Associate Professor of Pathology at Stanford Medical Center
  • Claude Coutinho, MD, PhD, MBA, President and CEO of Therapeutic Development-USA, Inc.
  • Julian Davies, PhD, FRS, Executive Vice President of Technology Development at Cubist Pharmaceuticals
  • Ronald Gray MD, at Johns Hopkins University School of Public Health and Director of the Center for VDT and Health Research
  • Vivek Shetty, DDS, DMD, Professor - Oral and Maxillofacial Surgery, Diagnostic and Surgical Sciences at UCLA


Dr. Luc Montagnier, PhD

Professor Luc Montagnier graduated in both Medicine and Biological Sciences at the University of Paris. At the age of 23, he became Assistant at this University. After a fruitful post-doctoral stay in two British laboratories, Montagnier spent most of his scientific carrier in two renowned French Institutions, the Institut Curie and for almost 30 years at the Institut Pasteur in Paris. Within the new Department of Virology of the latter Institute, he founded the Viral Oncology Research Unit. This laboratory devoted its activities to the study of cancer viruses, mostly the oncogenic retroviruses. Montagnier also studied the biochemical mechanisms which are at the origin of the growth in soft agar of virus transformed cultured cells, and evidenced the multi-step transformation of these cells based on their particular properties of growth in soft gels. In addition, his laboratory was involved in the discovery of interferon messenger RNA, opening the way for the cloning of the interferon genes and also showed the important role of interferon in the expression of retroviruses, including endogenous retroviruses.

In 1983, Montagnier led the team which first isolated the Human Immunodeficiency Virus (HIV1), a new type of retrovirus previously unrecognized in humans and brought the first evidence that this virus was the causative agent of AIDS. In 1985, he also isolated the second AIDS virus, HIV2, from West African patients. Montagnier’s laboratory was also the first to show that a large percentage of white blood cells of HIV infected patients were prone to die by apoptosis, a process of programmed cell death and to attribute its origin to the oxidative stress occurring in the patients, possibly associated with co-infections.

Besides his involvement in the design of new types of HIV vaccines, Montagnier’s current studies are aiming at the diagnosis and treatment of microbial, viral, and epigenetic factors associated with cancers, neurodegenerative and articular diseases, using innovative technologies. A strong advocate of preventive medicine, Montagnier is especially concerned with prolonging the active life of aging people.

Beyond his scientific interest is his deep commitment to helping developing countries acquire knowledge of and access to modern medicine and preventive medicine. As President of the World Foundation for Aids Research and Prevention, Montagnier has co-founded two Centers for the prevention, treatment, research and diagnosis of AIDS patients in the Ivory Coast and Cameroon.

Since 2005, as President-CEO and co-founder of Nanectis Biotechnologies SA, Paris, Montagnier developed a new biophysical technology detecting electromagnetic waves in the plasma of patients suffering from chronic degenerative diseases. These waves are induced in water dilutions by some DNA sequences, presumably originating from pathogenic bacteria and viruses. In the case of HIV infection, Montagnier showed that this technology can detect HIV DNA in patients treated by antiretroviral therapy and having no detectable virus load in the blood. This seminal discovery is opening the way to design new treatments aimed at functionally eradicating HIV infection.

Luc Montagnier has been honored worldwide with many awards, including the Rosen (1971), Gallien (1985), Korber (1986), and Jeantet (1986) Prizes, the Lasker Prize in Medicine (1986), the Gairdner Prize (1987), Sante Prize (1987), Japan Prize (1988), King Faisal Prize (1993), Amsterdam Foundation Prize (1994), Warren Alpert Prize (1998), Prince of Asturias Award (2000), the induction to the National Inventor Hall of Fame (2004). Montagnier is Commandeur de l’Ordre National du Merite (1986) and Grand Officier of the Legion of Honour (2009).

In 2008, Montagnier was awarded the Nobel Prize for Physiology and Medicine, for his discovery of HIV, together with Francoise Barre-Sinoussi.

Professor Montagnier is the author or co-author of 350 scientific publications and of more than 750 patents.

Dr. Ellen Jo Baron, PhD

Dr. Baron has been at Stanford since 1997, serving on the clinical faculty in the infectious diseases division. She directs the Stanford Clinical Microbiology/Virology Laboratory. Dr. Baron is an associate professor of pathology at the Medical Center effective April 2000 through March 2005. Dr. Baron received her PhD in medical microbiology with minors in biochemistry and bacteriology in 1981 from the University of Wisconsin, Madison. She worked in southern California as consulting director, microbiology and immunology, with Endocrine Sciences and as a consulting microbiologist with several area hospitals. She served as an adjunct associate professor at UCLA and as a clinical associate professor at the University of Southern California. In 1997 Baron received the prestigious Alice C. Evans Award from the American Academy of Microbiology in recognition of her scientific accomplishments, including the discovery of a previously unknown anaerobic bacterium. In 2000, she garnered the BioMerieux Sonnenwirth Award from the American Society of Microbiology. She is a fellow of the American Academy of Microbiology and of the Infectious Diseases Society of America. She currently chairs the American Board of Medical Microbiology. Dr. Baron also serves on the advisory board of the US FDA related to diagnostic devices.

Julian Davies, PhD, FRS

Dr. Julian Davies received his undergraduate and doctorate education from the University of Nottingham, U.K. Dr. Davies has taught at the University of Manchester, Harvard University, the University of Wisconsin and he was the Professor of biotechnology at the Pasteur Institute, Paris, France. He is currently the Emeritus Professor of Microbiology and Immunology at the University of British Colombia. He has made significant contributions to and acquired extraordinary experience in the Biotechnology industry as well. He was the President of Biogen in Switzerland and the founder of Terragen Diversity in Vancouver, Canada. He currently serves as Executive Vice President of Technology Development at Cubist Pharmaceuticals. Dr. Davies is the recipient of many scientific awards and has a long list of publications. He is a member of a number of scientific societies and past President of the American Society of Microbiology (1999-2000). He is a Fellow of the Royal Society and Royal Society of Canada.

Dr. Ronald H. Gray, MD, MSc, DTMH

Dr. Gray is a scientific advisor to ImmunoScience, Inc., Inc., Inc. Dr. Gray is a Professor at Johns Hopkins University School of Public Health and is a Director of the Center for VDT and Health Research. He has extensive contributions to the medical literature in the fields of epidemiology and public health. He has conducted research in various Asian and African countries, Australia, UK and the United States. Dr. Gray became aware of ImmunoScience, Inc., Inc.'s therapeutic vaccine while consulting with then honorable health minister of Uganda, Dr. Chrispus Kiyonga and has been optimistically excited about the prospect of a therapeutic vaccine.

Vivek Shetty, DDS, DMD

Dr. Shetty is is professor of Oral and Maxillofacial Surgery in the Diagnostic and Surgical Sciences Division at UCLA as well as the head of the Academic Senate at the same institution. He received his DDS from the University of Bombay, India and his Certificate in Oral/Maxillofacial Surgery from University of Regensburg, Germany. Among his various research interests is the identification of stress biomarkers in saliva.


Management Advisory Board


The Company also has a management advisory board whose members include:

  • Thomas Snyder, MBA
  • Ray Goldberg, MBA, PhD, professor emeritus at the Harvard Business School
  • R. Kenneth Bauer, JD
  • Sunil Patel

Thomas Snyder, MBA


Mr. Snyder is President/Owner of Cedar Valley Homes, a residential subdivision development and home construction company (since 2003). Prior to that, Tom was President of LMCB Financial Services, where he provided business consulting services primarily in the origination of capital for early stage development companies. He assisted in successfully raising over $35 million for such ventures. From 1992 to 1999 he was Director of the Columbus office of the University of Georgia Small Business Development Center, where he was also a lead instructor on business start-ups and also provided consulting services on finance and capital formation. He was Director of Practice Management for Columbus Regional Healthcare System, where he was responsible for physician recruitment and managing ten physician practices. Tom was the owner and manager of a multi-unit, multi-state garden and landscaping business for 12 years. He also served as a Senior Financial Analyst with Baxtor-Travenol after serving as a budget and supply officer with the US Navy from 1968 to 1971, with postings in Vietnam. Tom graduated from Princeton University with a BA in US History (cum laude) and earned an MBA from Harvard University.

Prof. Ray Goldberg, MBA, PhD


Professor Goldberg is a Professor Emeritus at Harvard Business School and a mentor of many of today's business leaders in the US and abroad. His area of expertise is biotech economics and special emphasis on agrotechnology. He has served or serves on the corporate boards of many eminent corporations such as ADM.

R. Kenneth Bauer, JD


Mr. Bauer received his JD from Santa Clara University. He has been in private practice of law for over 20 years and has extensive experience in litigations, contracts and corporate matters. He has been advising the Company since its inception.

Sunil Patel


Mr. Patel has received his MBA from George Washington University in International Business. His experience extends from international banking to heading green field projects as CEO in India and in the USA. During all this time he has accumulated extensive experience in project planning, progress maintenance and implementation. He has experience in working with diverse cultural groups with a major time spent in the US, India and Africa. He has a long association with ImmunoScience and will be actively involved in the areas of setting up collaborations and implementation of Phase 1 trials for Contre Vir™. Additionally his role in conceptualizing product launch and marketing will be extremely helpful to ImmunoScience.

In Memorium:

  • Claude B. Coutinho, MBA, PhD, MD, Dr. Coutinho was a distinguished scientist and physician with over thirty years of experience in the pharmaceutical/biotechnology/healthcare industry in the U.S.A and in Europe, as well as within the FDA as a pharmacologist/medical reviewer of domestic and foreign drug and medical device applications for approval.
  • Edwin Lennette, MD, PhD, known fondly as "father of virology in the United States" served on the advisory board from 1999 to 2002. He was an author of several textbooks on Virology and had an illustrious academic career with over 700 publications
  • George Leudemann, PhD, served on the advisory board from 1999 to 2000. He was a senior research scientist at Schering and the inventor of Gentamicin
  • Armin Ramel, PhD, served on the scientific advisory board from 1999 to 2005. He was a senior research scientist at Roche, Genentech and Scios
  • Prof. Milton R.J. Salton, PhD, DSc, FRS was a Professor Emeritus ant NYU and an author of over 500 scientific publications. He served on the scientific advisory board from 2000 to 2008.
  • Michael Schneider, Mr. Schneider had an illustrative career in business spanning decades. A self-made successful entrepreneur, he recently retired as Chairman and President of Romic Corporation which he managed for over a dozen years.